In swine myocardium, the infarct size reduction induced by U-89232 is glibenclamide sensitive: Evidence that U-89232 is a cardioselective opener of ATP-sensitive potassium channels

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 1, 1997, Pages 69-74

  Rohmann, Sven ^a   Fuchs, Claus ^a   Schelling, Pierre ^a  

^a MERCK KGAA   (Germany)

Author keywords

Cardioselective K(ATP) channel opener; Glibenclamide; Infarct size; U 89232

Indexed keywords

APRIKALIM; BIMAKALIM; CROMAKALIM; GLIBENCLAMIDE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; U 89232; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARDIOSELECTIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SELECTIVITY; HEART INFARCTION SIZE; HEART PROTECTION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BENZOPYRANS; CORONARY CIRCULATION; CORONARY VESSELS; GLYBURIDE; GUANIDINES; HEART; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; POTASSIUM CHANNELS; SWINE;

EID: 0031012791     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199701000-00011     Document Type: Article

References (35)

1. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1992; 20:765-71.
2. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989;20:1-9.
3. Grover GJ, Sleph PG, Dzwonezvk S. Pharmacological profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs. J Cardiovasc Pharmacol 1990;16: 853-64.
4. + channel opener RP 52891 reduces experimental infarct size in dogs in absence of systemic hemodynamic changes. J Pharmacol Exp Ther 1991;259:961-7.
5. Sassen LMA, Duncker DJGM, Gho BCG, Diekmann HW, Verdouw PD. Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br J Pharmacol 1990;101: 605-14.
6. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci 1990;47:1693-706.
7. Lynch JJ, Sanguinetti MC, Kimura S, Basset AL. Therapeutic potential of modulating potassium currents in diseased myocardium. FASEB J 1992;6:2952-60.
8. Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 1990;4:465-74.
9. Grover GJ, Dzwonezvk S, Sleph PG. Reduction of ischemic damage in isolated rat hearts by the potassium channel opener RP 52891. Eur J Pharmacol 1990;191:11-9.
10. + channel current in atrial myocytes of guinea pig heart. Jpn J Pharmacol 1990;54:473-7.
11. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
12. ATP-channels. Circulation 1994;89:1229-36.
13. Rohmann S, Weygandt H, Schelling P, Soei LK, Verdouw PD, Lues I. Involvement of ATP-sensitive potassium channels in preconditioning protection. Basic Res Cardiol 1994;89:563-76.
14. Grover GJ. Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia. Cardiovasc Res 1994; 28:778-82.
15. ATP-channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.
16. Toombs CF, Shebuski RJ. U-89232 (BMS-189365), a novel antiischemic agent derived from cromakalim. Cardiovasc Drug Rev 1995;12:303-16.
17. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, McCullough JR, Atwal KS. Cardioprotective profile of the cardiac selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
18. Hearse DJ. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30:1-17.
19. Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc Res 1995;30: 731-8.
20. Toombs CF, Moore TL, Shebuski RJ. Cardioprotection with U-89232 is not reversible with glibenclamide: evidence of a novel anti-ischemic agent derived from cromakalim. Pharmacology 1994;49:96-104.
21. Rohmann S, Weygandt H, Schelling P, et al. Effect of bimakalim (EMD 52692), an opener of ATP-sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine. Cardiovasc Res 1994;28:858-63.
22. Norman NR, Toombs CF, Khan SA, et al. Comparative effects of the potassium channel openers cromakalim and pinacidil and the cromakalim analog U-89232 on isolated vascular and cardiac tissue. Pharmacology 1994;49:86-95.
23. Toombs CF, Norman NR, Groppi VE, Lee KS, Gadwood RC, Shebuski RJ. Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo. J Pharmacol Exp Ther 1992;263:1261-8.
24. Atwal KS, Grower GJ, Ahmed SZ, Ferrara FN, Harper TW, Kim KS. Cardioselective anti-ischemic ATP-sensitive potassium channel openers. J Med Chem 1993;36:3971-4.
25. Imamura Y, Tomoike H, Narishige T, Takahashi T, Kasuya H, Takeshita A. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 1992;263:H399-404.
26. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat hearts. Am J Physiol 1992;263:H1107-12.
27. Grover GJ, Dzwonczyk S, Sleph PG. ATP-sensitive potassium channel activation does not mediate preconditioning in isolated rat hearts [Abstract]. Circulation 1992;86(suppl I):I-341.
28. Thornton J, Thornton CS, Sterling DL, Downey JM. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 1993;72: 44-9.
29. Downey JM. An explanation for the reported observation that ATP dependant potassium channel openers mimic preconditioning. Cardiovasc Res 1993;27:1565.
30. Gross GJ, Yao Z, Auchampach JA. Role of ATP-sensitive potassium channels in ischemic preconditioning. in: Przyklenk K, Kloner RA, Yellon DM, eds. Ischemic preconditioning: the concept of endogenous cardioprotection. Boston: Kluwer Academic Publishers, 1994:125-35.
31. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993;27:617-22.
32. Black CS, Lucchesi BR. Cardiovascular controversies: potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994;28:923-4.
33. Sanguinetti MC. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. Hypertension 1992;19:228-36.
34. Wilde AAM, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
35. Hofman D, Opie LH. Potassium channel blockade and acute myocardial infarction: implications for management of the non-insulin requiring diabetic patient. Eur Heart J 1993;14:1585-9.